Alnylam: Positive Topline Results from Phase 2 Study in IgA Nephropathy

 Cemdisiran Treatment Resulted in a 37 Percent Mean Reduction in 24-Hour Urine Protein to Creatinine Ratio, Relative to Placebo – a Key Prognostic Marker of Progression to End-Stage Kidney Disease in Patients with IgA Nephropathy -

- Acceptable Safety Profile, Supporting Continued Clinical Development -

- Full Results to Be Presented at Future Medical Congress -

https://finance.yahoo.com/news/alnylam-reports-positive-topline-results-110000435.html